Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
What the Clinical Data Shows Updated on December 23, 2025 to include the FDA approval of the Wegovypill by Novo Nordisk
As a multi-condition care provider for cardiometabolic and musculoskeletal (MSK) health, Omada Health is embracing the Return on Health framework to thoroughly articulate the value of care we provide and encouraging the virtual health industry to follow suit in service of establishing standardized industry expectations
Common dose-to-unit conversion table (3.33 mg/mL) Bookmark this table or save it on your phone
Prospective, single-arm, open-label, multicenter pilot study was carried out
US$ 26.64
US$ 24.82
US$ 20.28
